Jaume Capdevila Archives

Hypoxia-targeted therapy belzutifan shows promise in treating a rare type of neuroendocrine cancer

Results from the LITESPARK-015 open-label, multicohort phase 2 trial show that hypoxia-inducible factor-2 alpha inhibitor belzutifan achieves durable antitumor activity…

Novel targeted immunotherapy shows promise in a rare and highly aggressive group of neuroendocrine tumors

Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting* by Jaume Capdevila, a Medical Oncologist of the…

Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy

Initial results of the COMPETE phase 3 clinical trial⁠—the first study to compare targeted radioligand therapy with molecular targeted therapy…

Copia de Copia de Copia de Banner web VHIO (8)

First targeted radioligand therapy to demonstrate significant and clinically meaningful impact in first-line advanced gastroeneropancreatic neuroendocrine tumors

Co-authored by Jaume Capdevila, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH) and Senior Investigator of the Vall d’Hebron…

First targeted radioligand therapy to demonstrate significant and clinically meaningful impact in first-line advanced gastroenteropancreatic neuroendocrine tumors

Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…

Results of LIBRETTO-531 support selpercatinib as first-line treatment in patients with RET-mutant metastatic medullary thyroid cancer

Presented during Presidential session I (1) at the 2023 Congress of the European Society for Medical Oncology (ESMO), 20-24 October…

ESMO Congress 2022: VHIO co-led studies point to a potential new therapeutic strategy and treatment sequence for advanced neuroendocrine tumors

Results of the DUTHY exploratory phase II study evaluating dual immune checkpoint blockade with durvalumab and tremelimumab show promising activity…

ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer

Selected as an Oral Presentation during the American Society of Clinical Oncology (ASCO) 2021 Virtual Annual Meeting, 04 – 08…